药物性鼻炎的临床管理:一项系统综述
该系统综述检索PubMed、Embase、Cochrane和Web of Science数据库,纳入9项研究,评估药物性鼻炎(RM)的治疗方案。结果显示各研究结局指标高度异质且缺乏标准化,最常报告的治疗为局部鼻用糖皮质激素,但 overall 证据有限,不足以制定标准化治疗协议。作者呼吁建立统一问卷和标准结局指标,并开展前瞻性随机对照研究。
要点
- 药物性鼻炎缺乏标准化治疗协议,现有证据不足以推荐某一治疗优于其他。
- 局部鼻用糖皮质激素是文献中最常报告的治疗选择,但支持证据有限。
- 需统一结局指标并开展前瞻性随机对照研究以确定最佳治疗方案。
核心结论
- 现有证据不足以制定药物性鼻炎的标准化治疗协议。
- 需要开发统一问卷、标准结局指标及评估方法,并开展前瞻性随机对照研究。
研究设计与样本
- 系统综述,遵循PRISMA标准,检索PubMed、Embase、Cochrane和Web of Science数据库。
- 纳入9项英文研究,对象为长期使用局部鼻减充血剂后诊断为药物性鼻炎的患者。
- 使用MINORS标准评估非随机研究的质量。
主要发现
- 共识别350篇文章,最终9篇符合纳入标准进行定性分析。
- 各研究定义的结局指标高度异质,依赖多种非标准化测量方法。
- 最常报告的治疗选择是局部鼻用糖皮质激素。
关键数值与推荐
- 结局指标包括患者报告的症状缓解和客观参数,但各研究定义不一。
临床怎么用
- 临床处理药物性鼻炎时,局部鼻用糖皮质激素是文献中最常报告的选择,但需认识到证据有限。
- 应关注患者症状缓解和客观指标,但缺乏统一标准,需个体化评估。
局限性
- 纳入研究结局指标高度异质且非标准化,整体证据有限。
- 仅纳入英文文献,可能存在语言偏倚。
- 缺乏前瞻性随机对照研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Rhinitis medicamentosa (RM) is a common condition resulting from overuse of topical nasal decongestants. Despite the prevalence in otolaryngologic practice, a clear treatment protocol has not been established. Our objective was to review the current published literature pertaining to the treatment of RM with the possibility of finding data that support one treatment over another. DATA SOURCES: PubMed, Embase, Cochrane, and Web of Science databases were examined for patients diagnosed with RM resulting from chronic use of topical nasal decongestants. REVIEW METHODS: The PRISMA standard (Preferred Reporting Items for Systematic Reviews and Meta-analyses) was utilized to identify English-language studies reporting treatment of patients with the primary diagnosis of RM after chronic use of a topical decongestant. Outcome measures of interest included patient-reported symptom relief and objective parameters. MINORS criteria (methodological index for nonrandomized studies) were used to assess the quality of articles. RESULTS: A total of 350 articles were identified, 9 of which met final inclusion criteria for qualitative analysis. Outcomes defined in each publication were highly varied and relied on several unstandardized measures. The most commonly reported treatment option was topical nasal steroids, although overall there was limited evidence on which to base treatment recommendation. CONCLUSIONS: There is not adequate evidence to develop a standardized treatment protocol for RM. The development of a uniform questionnaire, standard outcomes to be measured, and a method of assessing such outcomes is necessary. Prospective randomized controlled studies are warranted to determine the optimal treatment regimen following diagnosis of RM.
引用
- Zucker SM, Barton BM, McCoul ED, et al. Management of Rhinitis Medicamentosa: A Systematic Review. Otolaryngol Head Neck Surg. 2018. PMID: 30325708. doi:10.1177/0194599818807891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。